Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. Monk BJ, et al. Among authors: freyer g. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284381 Free article. Clinical Trial.
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: freyer g. Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3. Eur J Cancer. 2023. PMID: 37263896 Free article. Clinical Trial.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: freyer g. Future Oncol. 2024;20(22):1531-1544. doi: 10.2217/fon-2023-0782. Epub 2024 Mar 19. Future Oncol. 2024. PMID: 38501262 Free PMC article. Clinical Trial.
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Kamrava MR, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick C, Lorusso D, Freyer G, O'Malley DM, York W, Malinowska IA, Monk BJ. Kamrava MR, et al. Among authors: freyer g. Gynecol Oncol. 2024 Oct;189:68-74. doi: 10.1016/j.ygyno.2024.07.006. Epub 2024 Jul 19. Gynecol Oncol. 2024. PMID: 39032397 Free article. Clinical Trial.
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz M, Morales S, Calero JB, Cortesi L, Pintér T, Palácová M, Cherciu N, Petru E, Ettl J, de Almeida C, Villanova G, Raymond R, Minh CTT, Rodrigues A, Cazzaniga ME. Freyer G, et al. Breast. 2024 Apr;74:103681. doi: 10.1016/j.breast.2024.103681. Epub 2024 Feb 9. Breast. 2024. PMID: 38377732 Free PMC article. Clinical Trial.
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?
Valenza C, Trapani D, Bidard FC, Gligorov J, Cortés J, Turner N, Dalenc F, Penault-Llorca F, Freyer G, Arnedos M, Villanueva C, Loibl S, Pistilli B, Curigliano G. Valenza C, et al. Among authors: freyer g. ESMO Open. 2024 Sep;9(9):103701. doi: 10.1016/j.esmoop.2024.103701. Epub 2024 Sep 3. ESMO Open. 2024. PMID: 39232441 Free PMC article.
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Nat Commun. 2024 Jun 4;15(1):4753. doi: 10.1038/s41467-024-48915-9. Nat Commun. 2024. PMID: 38834579 Free PMC article. No abstract available.
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Corbaux P, Freyer G, Glehen O, You B, Bakrin N, Gelot A, Dayde D, Sajous C, Piffoux M, Péron J, Lescuyer G, Payen L, Kepenekian V. Corbaux P, et al. Among authors: freyer g. Clin Cancer Res. 2024 Aug 15;30(16):3438-3446. doi: 10.1158/1078-0432.CCR-24-0507. Clin Cancer Res. 2024. PMID: 38819408 Clinical Trial.
271 results